Searchable abstracts of presentations at key conferences in endocrinology

ea0090s7.1 | Aberrant/illicit expression of receptors in adrenal lesions | ECE2023

GnRH in primary aldosteronism

Lacroix Andre

The mechanisms regulating aldosterone secretion in primary aldosteronism (PA) independently from the renin-angiotensin axis include diverse genetic and molecular mechanisms. One mechanism results from the activation of aberrantly expressed GPCR which are diverse and highly prevalent in adrenal tissues of patients with PA, either from aldosteronoma or bilateral adrenal hyperplasia. The levels of expression of GPCR vary greatly between different PA tissues particularly for ACTH ...

ea0049p3 | Update on regulation of steroidogenesis by aberrant hormone receptors | ECE2017

Update on regulation of steroidogenesis by aberrant hormone receptors

Lacroix Andre

The mechanisms regulating cortisol production when ACTH of pituitary origin is suppressed in primary adrenal causes of Cushing’s syndrome (CS) include diverse genetic and molecular mechanisms. These can lead either to constitutive activation of the cAMP system and steroidogenesis or to its regulation exerted by the aberrant adrenal expression of several hormone receptors, particularly G-protein coupled hormone receptors (GPCR) and their ligands. Screening for aberrant exp...

ea0064033 | A rare double cause of primary hyperparathyroidism | BES2019

A rare double cause of primary hyperparathyroidism

Hospel J , Lacroix V , Mourad M , Marbaix E , Camboni A , Furnica RM , Maiter D

Case: A 56-year-old patient was referred to our endocrinology unit for management of severe hypercalcemia. He had complained initially from asthenia, intractable nausea and vomiting and weight loss (10 kg), but now also suffered from polyuria-polydipsia, bradypsychia and bradylalia, and diffuse joint pain with loss of strength in the lower limbs. Initial laboratory investigations showed a parathyroid crisis with marked increases of parathyroid hormone (PTH) at 2138.5 pg/ml (45...

ea0041gp153 | Pituitary - Clinical | ECE2016

Once-monthly injection of pasireotide LAR reduces urinary free cortisol (UFC) levels in patients with Cushing’s disease: Results from a randomised, multicentre, phase III trial

Newell-Price John , Petersenn Stephan , Biller Beverly M K , Roughton Michael , Ravichandran Shoba , Lacroix Andre

Background: Twice-daily formulation of pasireotide, a pituitary-directed therapy, is approved for treatment of Cushing’s disease. Here we present data from a phase III study designed to evaluate the more convenient once-monthly long-acting release (LAR) formulation of pasireotide (approved for acromegaly) in patients with Cushing’s disease.Methods: Patients with persistent, recurrent, or de novo Cushing’s disease (not candidates for surger...

ea0081p405 | Pituitary and Neuroendocrinology | ECE2022

Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing’s disease treated with osilodrostat

Newell-Price John , Fleseriu Maria , Pivonello Rosario , Feelders Richard , Lacroix Andre , Auchus Richard , Piacentini Andrea , Pedroncelli Alberto , M.K. Biller Beverly

Background: 24-h mean urinary free cortisol (mUFC) and late-night salivary cortisol (LNSC) levels are complementary parameters recommended for screening and monitoring treatment response in patients with Cushing’s disease (CD). In the published core period of the Phase III LINC 3 study (NCT02180217), therapy with osilodrostat (potent oral 11β-hydroxylase inhibitor) produced rapid, sustained reductions in mUFC and LNSC alongside improvements in clinical signs of hyper...

ea0090rc5.4 | Rapid Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

Primary bilateral macronodular adrenal hyperplasia (PBMAH) is likely a genome instability disease due to ARMC5’s role in resolving transcription-replication conflict

Lao Linjiang , Bourdeau Isabelle , Gagliardi Lucia , He Xiao , Torpy David , Scott Hamish , Lacroix Andre , Luo Hongyu , Wu Jiangping

ARMC5 mutations are associated with PBMAH risks, but the ARMC5 action mechanism remains unknown. We discovered that ARMC5 was part of a novel ubiquitin ligase (E3) specific for RPB1, the largest Pol II subunit. ARMC5 deletion significantly reduced RPB1 ubiquitination and increased RPB1 accumulation. Surprisingly, the degradation of not only RPB1 but all the 12 subunits of Pol II was compromised in the absence of ARMC5, suggesting that this E3 acts on RPB1 and molecules in its ...

ea0049oc5.3 | Cardiovascular Endocrinology | ECE2017

Cardio metabolic assessment of lamin A/C mutation carriers according to R482 or Non-R482 mutation

Kwapich Maxime , Benomar Kenza , Espiart Stephanie , Belle Eric Van , Pigny Pascal , Bonne Gisele , Vigouroux Corinne , Lacroix Dominique , Vantyghem Marie-Christine

Background: Lamin A/C mutations show heterogeneous phenotypes expanding from cardiopathies to lipodystrophies. LMNA-related heart disease has recently been shown to be associated with a high incidence of phenotypic progression and adverse arrhythmic and non-arrhythmic events. Anticipatory planning to prevent sudden death has been recommended in a multicentric cardiologic recruitment. Nevertheless the specific cardiac prognosis of R482-LMNA mutated patients, the hot-spot for pa...

ea0049ep1039 | Pituitary - Clinical | ECE2017

Monthly pasireotide provides clinical benefit over 12 months in patients with Cushing’s disease

Pivonello Rosario , Bronstein Marcello , Schopohl Jochen , Delibasi Tuncay , Barkan Ariel , Suzaki Nori , Tauchmanova Libuse , Gupta Pritam , Petersenn Stefan , Lacroix Andre

Introduction: A monthly, long-acting formulation of pasireotide normalized or reduced mean urinary free cortisol (mUFC) in most patients with Cushing’s disease (CD) in a multicentre, double-blind, Phase III study. The effects of long-acting pasireotide on signs and symptoms of CD are reported here.Methods: Patients with persistent/recurrent (n=123) or de novo (non-surgical candidates; n=27) CD and mUFC≥1.5–5xULN...

ea0022p160 | Cardiovascular endocrinology and lipid metabolism | ECE2010

MRI-assessed visceral adipose tissue (VAT) in different lipodystrophic (LD) syndromes

Lucile Dieudonne , Claire Migaud Maria , Samuel Boury , Olivier Lascols , Dominique Lacroix , Philippe Mathurin , Jean-Louis Wemeau , Marie-Christine Vantyghem

Lipodystrophy (LD) and obesity are opposites in terms of a deficiency versus excess of adipose tissue mass, yet these conditions are accompanied by similar metabolic consequences. VAT has not been well quantified in LD. The aim of this study was to compare the metabolic profile and VAT in different kinds of LD. Six-eight adult patients (45 females) referred for LD were classified in four groups: 23 LMNA-mutated patients (LMNA), 14 non-mutated related to the LMNA-...

ea0084op-12-61 | Oral Session 12: Nodules and Diagnostic | ETA2022

Comparison of accuracy of 18F-fluorocholine PET-CT and PET/MR to 99MTC-sestamibi for the localization of hyperfunctioning parathyroid tissue in hyperparathyroidism

Mathey Celine , Ortansa-Irina Vierasu , Caroline Keyzer , Isabelle Delpierre , Nicola Trotta , Absil Julie , Lacroix Simon , Corvilain Bernard , Goldman Serge , Moreno-Reyes Rodrigo

Objectives: The aim of this prospective study was to compare the diagnostic performance of 99mTc-sestaMIBI SPECT scintigraphy (sestaMIBI), 18F-fluorocholine PET/CT or PET/MR (FCH) for preoperative localization of hyperfunctioning parathyroid gland.Materials and Methods: 60 patients with biochemical evidence of primary (n=57) or tertiary (n=3 kidney transplanted patients) hyperparathyroidism were imaged prospectivel...